BSE · 530991
Roopa Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹123 Cr with net profit ₹2 Cr — a 1.65% net margin, versus 2.12% the period before.
Shareholding
As of 2026-06-30
- Promoter48.03%
- Public51.72%
- FII0.25%
3,888 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.66× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #24 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,09,773 Cr | 279.12 | 12.49 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,031 Cr | 197.61 | 15.74 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,728 Cr | 68.48 | 13.2 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,418 Cr | 128.21 | 2.16 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,801 Cr | 68.84 | 2.45 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,571 Cr | 35.02 | 4.54 | 12.98% | 11.5% |
| Hikal Limited | ₹2,689 Cr | 186.43 | 2.25 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,256 Cr | 249.26 | 9.22 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 41.75 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,352 Cr | 68.98 | 3.24 | 17.67% | 13.66% |
| Roopa Industries Ltd.(this company) | ₹40 Cr | 9.86 | 2.28 | 23.13% | 6.28% |
AI analysis
AI-generated · google/gemini-2.5-flashRoopa Industries Ltd. is listed with a market capitalization of Rs 39 Cr. The company reported a revenue of Rs 122.98 Cr and a profit margin of 6.3%. Its earnings per share (EPS) stands at Rs 5.17, with a price-to-earnings (PE) ratio of 9.67. The book value is Rs 22.37. As of June 30, 2026, promoter holding was 48.0282%, and public holding was 51.7175%.
Positives
- +Return on equity (ROE) was 23.13%.
- +Revenue increased from Rs 71.5537 Cr in March 2024 to Rs 122.9836 Cr in March 2025.
- +The number of shareholders increased from 2950 in September 2016 to 3888 in June 2026.
Negatives
- −The company reported a negative net profit of Rs -1.43 Cr for the quarter ending March 2026.
- −The debt-to-equity ratio is 1.79.
- −Promoter holding decreased from 48.0282% in June 2026, though historical data is not available to show the full trend.
Financial Performance
Roopa Industries Ltd. reported a revenue of Rs 122.98 Cr for the fiscal year ending March 2025. This marks a significant increase from Rs 71.5537 Cr in March 2024. Net profit also rose to Rs 2.0349 Cr in March 2025, up from Rs 1.5191 Cr in March 2024. The company's EPS increased to Rs 2.57 in March 2025 from Rs 1.95 in March 2024.
Profitability & Returns
The company’s profit margin was 6.3%. Return on equity (ROE) was 23.13%, and return on capital employed (ROCE) was 15.3901%. The earnings per share (EPS) for the most recent fiscal year was Rs 5.17, contributing to a PE ratio of 9.67. For the quarter ending March 2026, the company reported a negative net profit of Rs -1.43 Cr.
Balance Sheet
Roopa Industries Ltd. has a debt-to-equity ratio of 1.79. The book value per share is Rs 22.37. No dividend yield was reported.
Ownership & Pledges
As of June 30, 2026, promoters held 48.0282% of the company's shares. Public shareholding stood at 51.7175%. Foreign institutional investors (FIIs) held 0.2543%. No shares were reported as pledged by the promoters. The number of shareholders as of June 30, 2026 was 3888.
Regulatory & Surveillance
No surveillance measures were reported for Roopa Industries Ltd.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.